Open for inclusion

Multi-arm, Non-randomized, Open-Label Phase IB Study to Evaluate GSK3052230 in Combination with Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects with Solid Malignancies and Deregulated FGF Pathway Signaling

Cancer type: Lung cancer

Phase: I

Principal Investigator: Lassen Ulrik

Country: DK

Keywords: Denmark, Rigshospitalet, Squamous NSCLC, FGFR1

Status: Open for inclusion

Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT01918254?term=BP28752&rank=1